Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P. Craven, Miroslawa Gorecka, David A. Broadbent, Peter Swoboda, Klaus K. Witte, Richard M. Cubbon, Hui Xue, Peter Kellman, John P. Greenwood, Sven Plein, Eylem Levelt
Hōputu: Artigo
Reo:Ingarihi
I whakaputaina: 2021
Urunga tuihono:https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ipurangi

https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf

Ngā tūemi rite